Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Veltassa
Veltassa 1 g powder for oral suspension Veltassa 8.4 g powder for oral suspension Veltassa 16.8 g powder for oral suspension Veltassa 25.2 g powder for oral suspension · Abschnitt 4.5 · PDF-Seite 6
HOS-224655 · Präparat HOS-217340
Concomitant administration of patiromer did not affect the bioavailability as measured by the area
under the curve (AUC) of amlodipine, cinacalcet, clopidogrel, furosemide, lithium, metoprolol,
trimethoprim, verapamil and warfarin. For these medicinal products no separation is needed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): furosemide (HOS-089060) trimethoprim (HOS-085184) amlodipine (HOS-086287) cinacalcet (HOS-128604) clopidogrel (HOS-087927) metoprolol (HOS-090094) lithium (HOS-085952) warfarin (HOS-085950) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-11T16:26:00Z · SHA-256 63e48efc0fe54dc2e178673f762548804da0e247a2277f0c1dd3c591d9e2953f · Passage a55ea681d08f94a49d98bfb3611fae5e4593314f034edb9b1a5464a1a64e27b9 · Zeichen 703–988 im Abschnitt
Wechselwirkungen · Segluromet
Segluromet 2.5 mg/850 mg film-coated tablets Segluromet 2.5 mg/1 000 mg film-coated tablets Segluromet 7.5 mg/850 mg film-coated tablets Segluromet 7.5 mg/1 000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-226405 · Präparat HOS-217580
Coadministration of metformin with
• Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.
• Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of
metformin.
• Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib,
isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in
metformin plasma concentration.
• Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal
elimination of metformin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): isavuconazole (HOS-085186) trimethoprim (HOS-085184) cimetidine (HOS-085835) crizotinib (HOS-116818) dolutegravir (HOS-089992) lead (HOS-085592) olaparib (HOS-130501) ranolazine (HOS-086141) vandetanib (HOS-119366) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-21T10:00:00Z · SHA-256 d06689c3556d840c8baeeb2685c51fa420383a5e9ae3cb83046dfca75d54ba34 · Passage d67107d6bf5a1829db69d8d540168041d14528191f7baa37904d08c09364de2a · Zeichen 3749–4348 im Abschnitt
Wechselwirkungen · Amglidia
AMGLIDIA 0.6 mg/mL oral suspension AMGLIDIA 6 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 8–10
HOS-226728 · Präparat HOS-217644
Anabolic steroids and male Potentiation of the Hypoglycaemia
sex hormones blood-glucose lowering
effect
Barbiturates Weakening of the Increased blood-glucose
blood-glucose lowering levels
effect
Beta-receptor blockers Potentiation of the Hypoglycaemia
blood-glucose lowering
effect
Signs of adrenergic Incorrect control of plasma
counter-regulation to glucose
hypoglycaemia may be
reduced or absent
Biguanides Potentiation of the Hypoglycaemia
blood-glucose lowering
effect
Bosentan Increase liver enzymes Incorrect control of plasma
glucose
Calcium channel blockers Weakening of the blood- Increased blood-glucose
glucose-lowering effect levels
Chloramphenicol Potentiation of the Hypoglycaemia
blood-glucose lowering
effect
Cimetidine Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Clarithromycin Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Clonidine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Potentiation or weakening of Incorrect control of plasma
the blood-glucose lowering glucose
effect
Signs of adrenergic counter- Incorrect control of plasma
regulation to hypoglycaemia glucose
may be reduced or absent
Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Colesevelam Reduction of glibenclamide Incorrect control of plasma
absorption from the glucose
gastrointestinal tract
Corticosteroids Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Coumarin derivatives Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Potentiate or weaken the Incorrect dose of coumarin
effect of coumarin derivatives administered
derivatives
Cyclophosphamides Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Diazoxide Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Disopyramide Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Diuretics Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Fenfluramine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Fenyramidol Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Fibrates Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Fluoxetine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Glucagon Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Guanethidine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Signs of adrenergic counter- Incorrect control of plasma
regulation to hypoglycaemia glucose
may be reduced or absent
H2-receptor antagonists Potentiation or weakening of Incorrect control of plasma
the blood-glucose lowering glucose
effect
Heparin Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Ifosfamide Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Insulin Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Isoniazid Weakening of the blood- Increased blood-glucose
glucoselowering effect levels
Large doses of laxatives Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Long-acting Potentiation of the blood- Hypoglycaemia
sulphonamides glucose lowering effect
MAO inhibitors Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Miconazole Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Nicotinic acid (in high Weakening of the blood- Increased blood-glucose
doses) glucose lowering effect levels
Oestrogens Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Other oral antidiabetics Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Oxypentifylline Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Oxyphenbutazone Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Phenothiazine derivatives Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Phenytoin Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Phosphamides Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Probenecid Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Progestogens Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Quinolone antibiotics Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Reserpine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Potentiation or weakening of Incorrect control of plasma
the blood-glucose lowering glucose
effect
Signs of adrenergic counter- Incorrect control of plasma
regulation to hypoglycaemia glucose
may be reduced or absent
Rifampicin Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Thyroid hormones Weakening of the blood- Increased blood-glucose
glucose lowering effect levels
Salicylates Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Sulfamethoxazole with Potentiation of the blood- Hypoglycaemia
trimethoprim (Co- glucose lowering effect
trimoxazole)
Tetracycline compounds Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Tritoqualine Potentiation of the blood- Hypoglycaemia
glucose lowering effect
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) fenfluramine (HOS-115627) tetracycline (HOS-115153) cimetidine (HOS-085835) clonidine (HOS-088594) diazoxide (HOS-088588) glucose (HOS-088412) coumarin (HOS-088372) heparin (HOS-086930) ifosfamide (HOS-091529) calcium (HOS-085615) disopyramide (HOS-085595) clarithromycin (HOS-084517) probenecid (HOS-085208) tritoqualine (HOS-115631) fluoxetine (HOS-085946) chloramphenicol (HOS-115623) guanethidine (HOS-088596) bosentan (HOS-086291) colesevelam (HOS-112356) isoniazid (HOS-088590) reserpine (HOS-088597) phenytoin (HOS-084531) glucagon (HOS-088589) miconazole (HOS-115630) oxyphenbutazone (HOS-226734)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-12-06T13:39:00Z · SHA-256 9b31c8fd2e2c11b31d3834841c43620453c6c194a0c4f4a1689401e4cae4ff04 · Passage 65768f222638b6ec5b55799dedba422cfd4ab929c394f7deccb2b45b8e583e53 · Zeichen 3453–12347 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-139155 · Präparat HOS-098290
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Grapefruit or grapefruit juice May increase tacrolimus whole Avoid grapefruit or grapefruit
blood trough concentrations and juice.
increase the risk of serious adverse
reactions (e.g., neurotoxicity, QT
prolongation) (see section 4.4).
Ciclosporin May increase tacrolimus whole The simultaneous use of
blood trough concentrations. In ciclosporin and tacrolimus
addition, synergistic/additive should be avoided (see section
nephrotoxic effects can occur. 4.4).
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus
nephrotoxic or neurotoxic neurotoxic effects of tacrolimus. with drugs known to have
effects: nephrotoxic effects should be
aminoglycosides, gyrase avoided. When co-
inhibitors, vancomycin, administration cannot be
sulfamethoxazole + avoided, monitor renal
trimethoprim, NSAIDs, function and other side effects
ganciclovir, aciclovir, and adjust tacrolimus dose if
amphotericin B, ibuprofen, needed.
cidofovir, foscarnet
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ibuprofen (HOS-087884) amphotericin B (HOS-109312) trimethoprim (HOS-085184) cidofovir (HOS-110482) grapefruit juice (HOS-088787) vancomycin (HOS-110486) ganciclovir (HOS-085194)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage 27fe058ee2f62d3423943030b75626c17ecf4d1bde53b7f6d6b5cf7025959525 · Zeichen 2054–3913 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 14
HOS-139183 · Präparat HOS-098290
As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing
hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene, or
spironolactone) should be avoided (see section 4.4). Care should be taken when tacrolimus is co-
administered with other agents that increase serum potassium, such as trimethoprim and cotrimoxazole
(trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a potassium-sparing diuretic like
amiloride. Close monitoring of serum potassium is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) amiloride (HOS-089052) triamterene (HOS-089051) trimethoprim (HOS-085184) potassium (HOS-086929) spironolactone (HOS-112481)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage 30e6eeb2317cdee4b7657b83f2d6f0c944b78efdd91aa2523ea6b7ddcf01974a · Zeichen 17205–17760 im Abschnitt
Wechselwirkungen · Ritonavir Viatris (previously Ritonavir Mylan)
Ritonavir Viatris 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-289163 · Präparat HOS-287148
Sulfamethoxazole/Trimethoprim2 800/160, single 500 q12 h ↓ 20%/↑ 20% ↔
dose
Dose alteration of sulfamethoxazole/trimethoprim during
concomitant ritonavir therapy should not be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T10:26:00Z · SHA-256 a3328f9af1f5f5ec5bfc660133bdb8ab6ed1eb58ad5187a900a91c8ec358a207 · Passage d26b1b1d10d2d7d740e1cc3d73bf4b165bdfef85372014347054745c00168a63 · Zeichen 37655–37965 im Abschnitt
Wechselwirkungen · Ritonavir Viatris (previously Ritonavir Mylan)
Ritonavir Viatris 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 22
HOS-289234 · Präparat HOS-287148
Thyroid hormone replacement
therapy
Levothyroxine Post-marketing cases have been reported indicating a potential
interaction between ritonavir containing products and
levothyroxine. Thyroid-stimulating hormone (TSH) should be
monitored in patients treated with levothyroxine at least the first
month after starting and/or ending ritonavir treatment.
ND: Not determined
1 Based on a parallel group comparison
2 Sulfamethoxazole was co-administered with trimethoprim
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T10:26:00Z · SHA-256 a3328f9af1f5f5ec5bfc660133bdb8ab6ed1eb58ad5187a900a91c8ec358a207 · Passage 711400da8b3ee57bef5dda391b2a2972626594ed54313a129ce6f3cc50e34c8a · Zeichen 59321–60084 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-142806 · Präparat HOS-098886
Lamivudine is cleared renally. Active renal secretion of lamivudine in the urine is mediated through the
OCT2 and multidrug and toxin extrusion transporters (MATE1 and MATE2-K). Trimethoprim (an inhibitor
of these transporters) has been shown to increase lamivudine plasma concentrations, however the resulting
increase was not clinically significant (see Table 1). Dolutegravir is an OCT2 and MATE1 inhibitor;
however, lamivudine concentrations were similar with or without co-administration of dolutegravir based on
a cross study analysis, indicating that dolutegravir has no relevant effect on lamivudine exposure in vivo.
Lamivudine is also substrate of the hepatic uptake transporter OCT1. As hepatic elimination plays a minor
role in the clearance of lamivudine, drug interactions due to inhibition of OCT1 are unlikely to be of clinical
significance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage 68ee1fb5f3c83148483c75b2a413f9c6ef89deaf94180a0dc56d65ed86568c73 · Zeichen 1083–1940 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-142833 · Präparat HOS-098886
9
Trimethoprim/sulfamethoxazole Lamivudine: No dosage adjustment necessary.
(Co-trimoxazole)/Lamivudine AUC 43%
(160 mg/800 mg once daily for Cmax 7%
5 days/300 mg single dose)
Trimethoprim:
AUC
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage 6c1daffb4bbef754510c0dafc6b1cb7302285fe046da310c0440fb06fe02db79 · Zeichen 15013–15307 im Abschnitt
Wechselwirkungen · Jayempi
Jayempi 10 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 11
HOS-292444 · Präparat HOS-287680
Where possible, concomitant administration of cytostatic medicinal products, or medicinal products
which may have a myelosuppressive effect, such as penicillamine, should be avoided (see section 4.4).
There are conflicting clinical reports of interactions, resulting in serious haematological abnormalities,
between azathioprine and trimethoprim/sulfamethoxazole.
There have been case reports suggesting that haematological abnormalities may develop due to the
concomitant administration of azathioprine and angiotensin-converting enzyme (ACE) inhibitors.
It has been suggested that cimetidine and indomethacin may have myelosuppressive effects which
may be enhanced by concomitant administration of azathioprine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) penicillamine (HOS-086112) trimethoprim (HOS-085184) cimetidine (HOS-085835) indomethacin (HOS-086115)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T16:20:00Z · SHA-256 3f7995b31b20577b7bbea6f2fe0b3eb850ff6826804870d7be27a8d0872d31ca · Passage 884454fd2473d6b9ca4146156262ad25a29d54012a5405f58e670ec8bd57699e · Zeichen 1420–2133 im Abschnitt
Wechselwirkungen · Kerendia
Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-145305 · Präparat HOS-099328
Certain medicinal products that increase serum potassium (see section 4.4)
Concomitant use of Kerendia with potassium supplements and trimethoprim, or
trimethoprim/sulfamethoxazole is anticipated to increase the risk of hyperkalaemia. Monitoring of
serum potassium is required.
Temporary discontinuation of Kerendia during trimethoprim, or trimethoprim/sulfamethoxazole
treatment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) potassium (HOS-086929)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T09:57:00Z · SHA-256 98ba233d390b44b94791f7f65cd1eff51a109db99630ace3897a132ef234b558 · Passage bc0303b67ca8047558df708bbeb781d1bef9cbe9698ad92b0a43ebff98b3e604 · Zeichen 2590–2987 im Abschnitt
Wechselwirkungen · Trepulmix
Trepulmix 1 mg/ml solution for infusion Trepulmix 2.5 mg/ml solution for infusion Trepulmix 5 mg/ml solution for infusion Trepulmix 10 mg/ml solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-293243 · Präparat HOS-287852
Gemfibrozil and other CYP2C8 inhibitors
Pharmacokinetic studies in humans with oral treprostinil diolamine indicated that the concomitant
administration of cytochrome P450 (CYP2C8) enzyme inhibitor gemfibrozil doubles the exposure
(both Cmax and AUC) to treprostinil. In case a CYP2C8 inhibitor (e.g. gemfibrozil, trimethoprim and
deferasirox) is added to or omitted from the patient’s treatment after the titration phase, a dose
adjustment of treprostinil has to be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): treprostinil diolamine (HOS-293244) trimethoprim (HOS-085184) deferasirox (HOS-088409) gemfibrozil (HOS-088403)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-31T17:11:00Z · SHA-256 062cea69b103ddb5291073cae569872cbbecd5f65c6036cdbd2ece246a9d7989 · Passage 302e2bca416267932bd5c5205802269c9fc0a51464a19798dbbc97bb9150887f · Zeichen 881–1359 im Abschnitt
Wechselwirkungen · Qaialdo
Qaialdo 10 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 7
HOS-295442 · Präparat HOS-288216
Concomitant use of medicinal products known to cause hyperkalaemia (such as lisinopril, valsartan,
indometacin) with spironolactone may result in severe hyperkalaemia.
In addition, concomitant use of trimethoprim/sulfamethoxazole (co-trimoxazole) with spironolactone
may result in clinically relevant hyperkalaemia.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) lisinopril (HOS-113010) valsartan (HOS-088810)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-14T09:00:00Z · SHA-256 93c960688dc364205e02a0072da45cb0a9d4d162cfd3be24dbd32f331fa3da62 · Passage 8650071237944b9b2d4208e64eafa5fbcb27fa2fd6a28307a1ef4cab6edef276 · Zeichen 108–423 im Abschnitt
Wechselwirkungen · Sapropterin Dipharma
Sapropterin Dipharma 100 mg soluble tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-148380 · Präparat HOS-099896
Although concomitant administration of inhibitors of dihydrofolate reductase (e.g. methotrexate,
trimethoprim) has not been studied, such medicinal products may interfere with BH4 metabolism.
Caution is recommended when using such medicinal products while taking sapropterin
dihydrochloride.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-18T14:15:00Z · SHA-256 7f489e5df6d8186bc2e2f84657777313e1b269ce048490600758b8ab4022b8eb · Passage 0af9e564199cb23003c27516a1fe80ebb90f2b93a51ae0753a4373ab8093dd94 · Zeichen 0–291 im Abschnitt
Wechselwirkungen · Sapropterin Dipharma
Sapropterin Dipharma 100 mg powder for oral solution Sapropterin Dipharma 500 mg powder for oral solution · Abschnitt 4.5 · PDF-Seite 20
HOS-148407 · Präparat HOS-099896
Although concomitant administration of inhibitors of dihydrofolate reductase (e.g. methotrexate,
trimethoprim) has not been studied, such medicinal products may interfere with BH4 metabolism.
Caution is recommended when using such medicinal products while taking sapropterin
dihydrochloride.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-18T14:15:00Z · SHA-256 7f489e5df6d8186bc2e2f84657777313e1b269ce048490600758b8ab4022b8eb · Passage 0af9e564199cb23003c27516a1fe80ebb90f2b93a51ae0753a4373ab8093dd94 · Zeichen 0–291 im Abschnitt
Wechselwirkungen · Paxlovid
Paxlovid 150 mg + 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-298850 · Präparat HOS-288868
14
Table 3: Interaction with other medicinal products and other forms of interaction
Medicinal product within
Medicinal product class
class (AUC change, Cmax Change) Clinical comments
reduction should be considered: for
patients with creatinine clearance of 30 to
60 mL/min the dose should be reduced by
50% (see section 4.2 for patients with
severe renal impairment).
Delamanid No interaction study is available with
ritonavir only. In a healthy volunteer drug
interaction study of delamanid 100 mg
twice daily and lopinavir/ritonavir
400/100 mg twice daily for 14 days, the
exposure of the delamanid metabolite
DM-6705 was 30% increased. Due to the
risk of QTc prolongation associated with
DM-6705, if coadministration of
delamanid with ritonavir is considered
necessary, very frequent ECG monitoring
throughout the full Paxlovid treatment
period is recommended (see section 4.4
and refer to the delamanid SmPC).
↑Erythromycin, Itraconazole increases AUC and Cmax of
↑Itraconazole* nirmatrelvir by 39% and 19%,
respectively. Ritonavir dosed as a
pharmacokinetic enhancer inhibits
CYP3A4 and as a result is expected to
increase the plasma concentrations of
itraconazole and erythromycin. Careful
monitoring of therapeutic and adverse
effects is recommended when
erythromycin or itraconazole is
coadministered with ritonavir.
↑Fusidic acid (systemic route) Given the risk of substantial increase in
fusidic acid (systemic route) exposure and
thus of its related adverse events,
coadministration should not be used unless
a multidisciplinary consultation could be
obtained to safely guide it.
↑Rifabutin (4-fold, 2.5-fold), An increase in rifabutin exposure is
↑25-O-desacetyl rifabutin expected due to the inhibition of CYP3A4
metabolite (38-fold, 16-fold) by ritonavir. The consultation of a
multidisciplinary group is recommended to
safely guide the co-administration and the
need of a reduction of the rifabutin dose.
Rifampicin, Rifampicin and rifapentine are strong
Rifapentine CYP3A4 inducers, and this may lead to a
decreased exposure of
nirmatrelvir/ritonavir, potential loss of
virologic response and possible resistance.
Concomitant use of rifampicin or
rifapentine with Paxlovid is
contraindicated (see section 4.3).
Sulfamethoxazole/trimethoprim Dose alteration of
sulfamethoxazole/trimethoprim during
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) lopinavir (HOS-086269) trimethoprim (HOS-085184) fusidic acid (HOS-086146) rifabutin (HOS-086262) creatinine (HOS-086273) lead (HOS-085592) itraconazole (HOS-084516) erythromycin (HOS-084514) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-18T16:10:00Z · SHA-256 4b23ba150bb95800cdeb540cb63b825f728eec67d797b93e35c159d72997da80 · Passage ee3ae76ca6965de44e6b1e672d2faddb4c509da4853f644324b4b59b22e9ec3e · Zeichen 37028–42070 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.